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Upper respiratory tract infection (URTI) can compromise athlete preparation and performance, so 31 
countermeasures are desirable. The aim of this study was to assess the effects of ColdZyme® 32 
Mouth Spray (ColdZyme) on self-reported upper respiratory tract infection in competitive 33 
endurance athletes under free-living conditions. 34 
One hundred and twenty-three endurance-trained, competitive athletes (recruited across 4 sites in 35 
England, UK) were randomised to control (no treatment, n = 61) or ColdZyme (n = 62) for a 3-36 
month study period (between December 2017 – February 2018; or December 2018 – April 2019). 37 
They recorded daily training and illness symptoms (Jackson common cold questionnaire) during the 38 
study period.  39 
A total of 130 illness episodes were reported during the study with no difference in incidence 40 
between groups (episodes per person: 1.1 ± 0.9 Control, 1.0 ± 0.8 ColdZyme, P = 0.290). Episode 41 
duration was significantly shorter in ColdZyme compared to Control: Control 10.4 ± 8.5 days vs 42 
ColdZyme 7.7 ± 4.0 days, P = 0.016). Further analysis to compare episodes with poor vs good 43 
compliance with ColdZyme instructions for use (IFU) within the ColdZyme group showed a further 44 
reduction in duration of URTI when compliance was good (9.3 ± 4.5 days in ColdZyme poor IFU 45 
compliance vs 6.9 ± 3.5 days in ColdZyme good IFU compliance, P = 0.040). 46 
ColdZyme may be an effective countermeasure to reduce URTI duration, which was significantly 47 
lower (by 26-34%) in the ColdZyme treatment group (with no influence on incidence). This may 48 
have implications for athlete performance. 49 
 50 
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The incidence of upper respiratory illnesses is higher than normal in some groups of athletes, and 69 
such infections can compromise training and/or competition performance.1 Endurance athletes are 70 
often associated with a higher than normal incidence of infections, especially of the upper 71 
respiratory tract (URTI).2,3 This is typically related to a high training load and/or heavy competition 72 
schedule. More recent debates have questioned whether athletes do experience a higher incidence, 73 
compared to the general adult population (i.e. one to three individual episodes of upper respiratory 74 
tract infection per year4,5). However, it is clear that reporting of upper respiratory symptoms (URS) 75 
in athletes cluster around periods of intensive training and/or competition.6,7 Experiencing URTI or 76 
illness symptoms can result in a loss of training days and a performance decrement (6,8,9) so 77 
strategies to reduce the risk of contracting these illnesses may be of direct benefit to athletes. This 78 
may also limit the risks of spreading infection to others (i.e. teammates). The possible links between 79 
URTI incidence and athletic performance is highlighted by research showing World Championship 80 
and Olympic medal winning athletes reported fewer URS than less successful athletes.6,10,11 This is 81 
likely related, at least in part, to the ability (and resource) to successfully implement strategies that 82 
reduce URTI risk.12,13  83 
 84 
Strategies to minimise the risk of contracting a URTI and/or reduce time taken to clear an infection 85 
have focussed on avoidance of exposure and minimising the controllable risk factors that are 86 
associated with lowered immune defence (e.g. intensified training, life stressors), but these may be 87 
difficult to avoid for many athletes.6,14 Other strategies have focussed on nutritional interventions 88 
purported to reduce the immune perturbations caused by strenuous exercise and training. 89 
Unfortunately, many such strategies have limited success.11–15 An alternative strategy that has 90 
received little attention in athletic populations, is the use of products that may inhibit viral 91 
infectivity (for example, via limiting viral entry or replication/propagation after initial exposure). 92 
Most URTIs are caused by viral infection, with over 200 known viruses, the most common being 93 
rhinoviruses, coronaviruses, influenza viruses, adenoviruses, parainfluenza viruses, respiratory 94 
syncytial viruses and enteroviruses.16 Infection is initially established in the mucosa of the 95 
nasopharynx before spreading anteriorly, through the nasal region (17), with local symptoms 96 
typically beginning in the throat before nasal congestion, rhinorrhoea, sneezing and cough tend to 97 
develop.18 98 
  99 
It is possible that inhibiting viral propagation in this area during the incubation period, may prevent 100 
or shorten the duration of viral URT infection. ColdZyme® Mouth Spray (ColdZyme) consists of a 101 
hyperosmotic glycerol solution containing cold-adapted trypsin from the Atlantic cod (Gadus 102 
morhua) and has been shown to reduce URTI duration in a number of studies in healthy and clinical 103 
(i.e. non-athletic) populations.19,20 It is suggested that orally spraying of the solution forms a 104 
temporary barrier on the pharynx that prevents viral binding and entry. The idea that local effects in 105 
this part of the URT can successfully reduce URTI duration is also supported by other studies 106 
showing effective protection against the common cold with substances administered orally (e.g. 107 
zinc lozenges 21). ColdZyme spray solution has demonstrated broad antiviral activity in vitro, 108 
deactivating 64-100% of virus activity for common URTI-causing pathogens (influenza virus, 109 
rhinovirus, adenovirus and coronavirus).22 Clarsund et al. (19) found that ColdZyme treatment was 110 
effective against the common cold in healthy adults inoculated with rhinovirus-16: most notably the 111 
duration of illness was reduced by 54% in those who were infected. Also, Clarsund et al. (20) 112 
reported a case study of a 12-year old boy with common variable immunodeficiency, and found a 113 
reduction in reported common cold infection and a 3-fold decrease is missed school days when 114 
using ColdZyme. However, no randomised controlled trials have examined whether such products 115 
can reduce URTI/URS incidence or duration in athletic populations. One recent study (23) did 116 
examine ColdZyme in athletes, but it lacked a control group and made comparisons with 117 
retrospective historical data from athlete’s own training diaries, which has obvious limitations for 118 
establishing efficacy. The aims of this study were, therefore, to assess the efficacy of ColdZyme on 119 
URTI incidence, symptom ratings, and missed (or reduced) training in competitive endurance 120 





Type of Study:  126 
Prospective, open label, parallel groups, randomised controlled trial.  127 
 128 
Participants:   129 
Endurance-trained; competitive athletes (e.g. long-distance runners; triathletes; cyclists) were 130 
recruited. Participants were excluded if on long term medication; currently smoking; allergic to 131 
any of the ingredients in ColdZyme; had any other current medical conditions that may be 132 
aggravated by use of the product; were currently using any medication (except for 133 
contraceptives), or food supplements; were currently using any other relevant products or 134 
supplements (nutritional or otherwise) that may influence the common cold; were currently 135 
taking part in another study that may compromise results of this study; or were pregnant, breast-136 
feeding or planning to become pregnant during the study. 137 
 138 
Ethical approval:  139 
The study was conducted in accordance with the Declaration of Helsinki and approved by the 140 
ethics committees of the authors’ Universities. All participants were informed, both verbally and 141 
in writing, of the nature and risks of the study before giving their written consent to take part.  142 
 143 
Design:  144 
Athletes were monitored over a 3-month period of using ColdZyme product (or control). During 145 
this period they completed self-report training logs, and the Jackson common cold questionnaire 146 
(24). The ColdZyme group were also required to keep a personal record of product usage. The 147 
study period was in UK winter months. Tranche 1 took place between December 2017 – March 148 
2018 and Tranche 2 took place between December 2018 and April 2019. Tranche 1 took place 149 
in Southeast England (East Kent and Medway areas). Tranche 2 took place in Southeast 150 
England, as in Tranche 1, plus at 3 additional sites: Tonbridge, UK; Merseyside, UK, and 151 
Lincolnshire, UK. Participants were stratified by sport type, sex, age, and usual training volume 152 
and randomised to either control or ColdZyme group by random number generation 153 
(www.randomization.com). Randomisation was also applied at each site independently so that 154 
groups were matched within each location. The allocation schedule was concealed from 155 
investigators involved in recruiting the participants, hence group allocations were only provided 156 
one at a time.  157 
 158 
Treatment:  159 
Participants in the treatment (ColdZyme) group were asked to use the ColdZyme product in 160 
accordance with manufacturer instructions for treatment of suspected common cold/URTI (at 161 
first self-perceived signs of URTI). Briefly, this included instruction to spray 2 times (1 dose) 162 
every second hour up to 6 times daily.  163 
 164 
Participants in the control group were asked to continue with their normal training, to log all 165 
activities and URTI (Jackson questionnaire) but were not provided with ColdZyme. Participants 166 
were not restricted from using over-the-counter (OTC) medication if they felt it necessary, but 167 
were required to record any usage in their illness log.  168 
 169 
Training monitoring: 170 
Participants were required to log s every exercise training session. They were required to 171 
provide details on exercise type, duration and a single overall rating of their perceived exertion 172 
for the session (using the session rating of perceived exertion method, sRPE 25).  173 
 174 
Monitoring of upper respiratory illness: 175 
Participants were required to complete the Jackson questionnaire daily (24). Completion of this 176 
prospective questionnaire first requires participants to indicate if they believe they are suffering 177 
from a common cold/URTI. If they answer yes to the initial question, they must then rate which 178 
of the 8 Jackson score symptoms they are suffering (headache, chilliness, sneezing, sore throat, 179 
malaise, cough, nasal discharge, nasal obstruction) and give a rating of the severity of each 180 
symptom experienced (0, none; 1, mild; 2, moderate; 3, severe). An episode of URTI was 181 
defined using the Jackson criteria (as applied by Martineau et al.26): scores for each of 8 182 
symptoms were summed for each day to generate a total Jackson score, and an episode was 183 
defined as those lasting ≥ 3 days and with either i) a total Jackson symptom score of ≥14 + 184 
subjective impression of having a cold (question 1), or ii) a total Jackson symptom score of ≥14 185 
+ nasal discharge for at least 3 days, or iii) a total Jackson symptom score <14 + subjective 186 
impression of having a cold + nasal discharge for at least 3 days.  187 
 188 
Data analysis:  189 
All data analysis was conducted using IBM SPSS statistics version 25 (IBM, Armonk, NY). 190 
Data were checked for normal distribution prior to analysis. Data that did not have a normal 191 
distribution (sRPE-based training load) were normalised via log transformation prior to analysis. 192 
Data that could not be normalised by log or square root transformation (missed and reduced 193 
training) were analysed with non-parametric tests. Group comparisons were made using 194 
independent samples t-test (or for missed and reduce training data, Mann-Whitney U test; and 195 
for OTC medication use, chi-squared analysis). Training load variables were compared between 196 
groups, and across repeated time-points (weekly over study period, and weeks before, during 197 
and after URTI episodes) with 2-way mixed ANOVA (between factor: group, and within 198 
group/repeated factor: time point). Post hoc paired t-tests were used, where necessary, to 199 





A total of 130 subjects were enrolled, but 7 were lost to follow-up (n = 3 [2 Control, 1 ColdZyme] 205 
due to injury meaning no regular training during study period; n = 2 [1 Control, 1 ColdZyme] 206 
voluntarily withdrew before completion; n = 2 [1 Control, 1 ColdZyme] did not return logs and 207 
could no longer be contacted/did not reply to communications). Analysis was completed on n = 123 208 
(n = 61, age 39.3 ± 11.5 years, control and n = 62, age 39.5 ± 12.1 years, ColdZyme; male n = 60, 209 
female n = 63). Athletes were all competitive endurance athletes in current training, ranging from 210 
club level athletes to age-group international level, with comparable average training load in each 211 
group (see below). The majority of athletes were runners (n = 38 control, n = 44 ColdZyme), then 212 
triathletes (n = 13 control, n = 13 ColdZyme) and cyclists (n = 8 control, n = 4 ColdZyme) with a 213 
small number from other sports (swimming n = 1 control, n = 1 ColdZyme; and rowing n = 1 214 
ColdZyme).   215 
 216 
At least one URTI episode was recorded during the study period in 76.4% of all participants (77.0% 217 
control, 75.8% ColdZyme). In total 130 episodes were recorded by all participants over the study 218 
period with no difference between groups in the incidence rate (mean incidence rate per person over 219 
study period was: 1.1 ± 0.9 Control, 1.0 ± 0.8 ColdZyme, P = 0.290). Symptom duration and 220 
severity ratings were also lower in the ColdZyme group (see Table 1). 221 
 222 
***Please insert Table 1 near here*** 223 
 224 
Symptoms duration  225 
Overall Control vs ColdZyme mean episode duration was 10.4 ± 8.5 days in Control and 7.7 ± 4.0 226 
days in ColdZyme (P = 0.016, see Table 1). On further examination of usage records and diaries 227 
from Tranche 1 (December 2017-February 2018) it became apparent that, despite being instructed 228 
to follow the manufacturer’s IFU (i.e. to use 1 dose every second hour up to 6 times daily), not all 229 
of the participants in the ColdZyme group followed the recommendations for use (~37% of 230 
recorded episodes were not treated according to the ColdZyme IFU). For Tranche 2 (December 231 
2018-March 2019) we provided additional information and regular reminders to participants to 232 
overcome this. These procedures appear to have been effective as poor compliance with IFU was 233 
only evident in 14% of reported episodes. Nevertheless, these subjects/episodes (with poor IFU 234 
compliance) from both Tranches do provide a useful comparator group for some statistical 235 
comparisons, which may overcome some of the limitations that arise in open label trials (i.e. 236 
potential placebo effects in treatment group). Poor compliance with IFU was considered as not 237 
using the ColdZyme product in accordance with guidelines (i.e. less than 4 doses per day). When 238 
those randomised to ColdZyme but with poor compliance (Poor IFU comp) were separated from 239 
those with good compliance (Good IFU comp) the observed effect between Control and ColdZyme 240 
groups becomes even more evident (episode duration 10.4 ± 8.5 days in Control vs 6.9 ± 3.5 days in 241 
ColdZyme Good IFU comp, P = 0.004). Direct comparison between compliance groups also shows 242 
a significantly shorter episode duration with good compliance (episode duration 9.3 ± 4.5 days in 243 
ColdZyme poor IFU comp vs 6.9 ± 3.5 days in ColdZyme Good IFU comp, P = 0.040). 244 
 245 
Jackson Symptom Score  246 
Total symptom score during episode: This parameter shows the overall symptom impact (product 247 
of number of Jackson symptoms and symptom severity ratings, and accounting for episode 248 
duration). Overall Control vs ColdZyme mean Jackson symptom score was 74.9 ± 72.0 in Control 249 
and 43.6 ± 30.1 in ColdZyme (P = 0.003, see Table 1). When comparing episodes with good and 250 
poor IFU compliance, the ColdZyme Good IFU comp group had a significantly lower symptom 251 
score (40.0 ± 26.5) than the Control group (P = 0.002), whereas the Poor IFU comp group (52.6 ± 252 
35.7) were not significantly different from control (P = 0.100). Direct comparison between the 253 
episodes with bad and good IFU compliance did not show any statistically significant difference 254 
however (P = 0.152).  255 
 256 
Average symptom score per day during episode: This parameter is directly related to the severity 257 
rating and number of symptoms experienced on average (per day) in each episode. Overall Control 258 
vs ColdZyme mean Jackson symptom score was 6.9 ± 2.8 in Control and 5.5 ± 2.4 in ColdZyme (P 259 
= 0.006, see Table 1). When comparing episodes with good and poor IFU compliance, the 260 
ColdZyme Good IFU comp group had a significantly lower symptom score (5.6 ± 2.7) than the 261 
Control group (P = 0.014), and so did the ColdZyme Poor IFU comp group (5.3 ± 1.7) (P = 0.033). 262 
Direct comparison between the episodes with bad and good IFU compliance did not show any 263 
statistically significant difference (P = 0.481).  264 
 265 
Daily training logs 266 
Participants typically trained between 4 and 10 h per week. Participants were asked to record every 267 
training session (duration and sRPE) in their training logs. Training ‘load’ was quantified as the 268 
product of sRPE and duration for each session (and summed each week). Sufficient detail to allow 269 
full analysis of training data was provided by 93 participants (whereas 19 participants [n = 9 270 
Control, n = 10 ColdZyme] failed to record sRPE but recorded details on training type and duration, 271 
and 11 participants [n = 9 Control, n = 10 ColdZyme] failed to record either sRPE or duration).  272 
 273 
For the 93 subjects with complete training logs, there were no significant between-group differences 274 
in training load or the profile of training load across the study period (2-way mixed ANOVA: group 275 
P = 0.925; time P = 0.055; group × time P = 0.626). For the n = 19 who did record duration only 276 
there was no difference in average weekly training time (Control 6.0 ± 1.5 h; ColdZyme 5.9 ± 1.8 h, 277 
P = 0.851).  278 
 279 
For analysis of training load data (see Figure 1) each subject’s average healthy (i.e. when not 280 
experiencing or recovering from a URTI episode or injury) value was calculated and training load 281 
profile across the 12-week period expressed as a percentage of this. There was a trend for training 282 
load to increase across the study period although this did not reach statistical significance, but 283 
importantly this pattern did not differ between groups. There was a significant reduction in training 284 
load during the weeks in which URTI episodes were experienced (P < 0.01 compared to other, none 285 
URTI weeks, see Figure 2), however, this did not differ between groups (2-way mixed ANOVA: 286 
group P = 0.424; time P < 0.001; group × time P = 0.269). There was also no difference in the rate 287 
of return to normal training load, following reported URTIs, between groups.   288 
 289 
***Please insert Figure 1 near here*** 290 
 291 
***Please insert Figure 2 near here*** 292 
 293 
 294 
Missed and reduced training days 295 
 296 
***Please insert Table 2 near here*** 297 
 298 
Missed training 299 
The number of missed training days (caused by URTI episode/symptoms etc) was significantly 300 
lower in the ColdZyme compared to Control group (P = 0.013, see Table 2). When considering IFU 301 
compliance, there were significant differences between Control and ColdZyme Good IFU comp (P 302 
= 0.021) and ColdZyme Poor IFU comp (P = 0.045). There was no significant difference between 303 
ColdZyme Good and Poor IFU comp however (P = 0.406).  304 
 305 
Reduced training 306 
The number of days on which training was reduced, as a consequence of an episode, was not 307 
significantly different between the ColdZyme and Control groups (P = 0.475 see Table 2). When 308 
considering IFU compliance, there were no significant differences between Control and ColdZyme 309 
Good IFU comp (P = 0.288) or ColdZyme Poor IFU comp (P = 0.336). There was also no 310 
significant difference between ColdZyme Good and Poor IFU comp (P = 0.269).  311 
 312 
Use of OTC medication 313 
Participants felt the need to use OTC medication for 48% of cases (32/67 episodes) in Control and 314 
38% of cases (24/63 episodes) in ColdZyme, with no difference between groups (χ2 P = 0.266). The 315 
OTC medications used were most commonly cold and flu formulations (e.g. Lemsip; Control = 14, 316 
ColdZyme = 11), followed by analgesics (e.g. paracetamol (acetaminophen); Control = 12, 317 
ColdZyme = 12), with others used rarely (throat lozenges or cough mixture, Control = 5, ColdZyme 318 
= 0; and decongestants, Control = 1, ColdZyme = 1).  319 
 320 
Adverse events reporting 321 
One participant reported a potential adverse event (unsettled stomach) during the study, in the 322 
ColdZyme (treatment) group. It was not serious and no special treatment was necessary. No other 323 
adverse events were reported by any participant. 324 
 325 
Discussion 326 
This is the first randomised controlled trial to examine the efficacy of ColdZyme mouth spray on 327 
URTI outcomes in athletes (and the first to study any intervention of a product purported to act via 328 
local mechanisms of inhibiting viral infectivity and propagation in the URT). The main finding 329 
from this study is that ColdZyme did not alter the chances of contracting a URTI (no effect on 330 
URTI incidence) but it was able to reduce the duration for which URTI symptoms persisted, and 331 
reduce mean daily ‘severity’ ratings, in competitive endurance athletes. This benefit was evident in 332 
the ColdZyme group overall, with further analysis showing that the benefit was significantly more 333 
apparent when compliance was good (i.e. ~26% vs ~34% shorter episode duration) but was lost for 334 
duration if compliance with the IFU was poor. The ColdZyme group also reported fewer missed 335 
training days as a consequence of URTI episodes. The average episode duration was ~10.4 days in 336 
the control group, 7 days of which (~66%) resulted in compromised training (~3.4 d reduced 337 
training and 3.5 d missed training per episode). In the ColdZyme group episodes of URTI had less 338 
of an effect on compromising training (4.6 of 7.7 d [~60%]), with the difference resulting from 339 
significantly less missed training days (Control 3.5 of 10.4 d [~34%] missed training days per 340 
episode, and ColdZyme 1.6 of 7.7 d [~21%] missed training days per episode). These results 341 
suggest that ColdZyme mouth spray can reduce symptom duration and severity ratings (during a 342 
self-reported URTI) in endurance athletes, consequently reducing the number of missed training 343 
days. This may help to reduce the negative impact of an illness episode on athlete performance, 344 
since a loss of training days is associated with performance decrement in athletes (6,8,9). ColdZyme 345 
is a potential countermeasure to reduce the negative impact caused by such illness.  346 
 347 
ColdZyme has been shown to have broad-range antiviral activity against common URTI-causing 348 
viruses in vitro, deactivating 64-100% of virus activity for influenza virus, rhinovirus, adenovirus, 349 
and coronavirus (22). A possible mechanism for the present results, therefore, is that the oral 350 
application via spraying forms a temporary barrier on the oropharynx that prevents viral binding 351 
and entry, and that the regular reapplication (i.e. up to 6 times per day, in line with manufacturer 352 
IFU) can inhibit viral propagation to a sufficient extent so as to reduce viral load and allow a more 353 
rapid clearance of infection in endurance athletes. The fact that the spray is applied to the throat 354 
suggests that the oropharynx is an important area for propagation and target for treatment. This is 355 
further supported, for example, by the reduction in common cold duration that has been observed 356 
with the use of zinc gluconate lozenges (21). Indeed, this is in line with previous research on 357 
ColdZyme using the quarantine human viral challenge model with rhinovirus-16 (19). The present 358 
study, however, is the first to examine ColdZyme in free living/real-world conditions in a 359 
randomised controlled trial with athletes.  360 
 361 
It is possible that some findings of this study may be influenced by the open label nature of the trial. 362 
For the primary outcomes (URTI reporting) previous research (27) has shown that the magnitude of 363 
the placebo effect has a small influence on URTI reporting (see further discussion in limitations 364 
below). For the other (secondary) parameters, such as missed or reduced training, we are not aware 365 
of any research on how the placebo effect may influence these. Ultimately, the decision to deviate 366 
from planned training is a choice made by the athlete so it is possible that the placebo effect 367 
influences this to a greater extent. However, a possible explanation for our findings for missed 368 
training days could also be that both poor IFU compliance and good IFU compliance groups 369 
reported significantly lower average daily severity ratings than the control group. Indeed, it would 370 
seem logical that symptom severity would be the most important factor influencing athletes’ 371 
decisions about whether to train as normal, reduce training or miss training altogether. We also 372 
cannot exclude the possibility that those in the treatment group felt more willing to continue with 373 
training as they knew they were receiving an intervention that may help.  374 
 375 
Limitations 376 
The main limitation is the open label nature of this study, which presents the possibility of a placebo 377 
effect in the treatment group and/or a nocebo effect in the control group. At the time of 378 
commencing the study, the manufacturer was not able to provide an appropriate placebo. Future 379 
research would be enhanced with a full placebo so that a fully placebo-controlled, double-blind 380 
design could be implemented. Although previous research has shown that knowledge of the 381 
treatment does not influence objective biomarkers of immune function in response to exercise (e.g. 382 
immune cell functions 29, 30), self-report results for URTI parameters are likely more prone to 383 
influence. Research on the placebo effect has shown only modest placebo effects for common cold 384 
symptoms, with an episode duration comparable to the present study (27). In this study they 385 
observed an effect size below the minimal threshold for a small effect (for common cold duration 386 
27), whereby the placebo effect influenced average reported duration by less than 0.7 days (i.e. 387 
<10%) and severity ratings by 8-17%. However, the effect was larger for individuals who had a 388 
higher belief in the possible beneficial effects (i.e. expectation) at the point of enrolment. It is 389 
possible therefore that some individuals in the ColdZyme group had positive expectations, which 390 
could have influenced their URTI scores. Unfortunately we did not capture data on expectations in 391 
the treatment group, and this would be beneficial to include in future studies (although an 392 
appropriate placebo is preferable).   393 
 394 
On examination of usage records and diaries from Tranche 1 (December 2017-February 2018) it 395 
became apparent that, despite being instructed to follow the manufacturer IFU (i.e. 1 dose every 396 
second hour up to 6 times daily), not all of the participants in the ColdZyme group followed the 397 
recommendations for use (~37% of recorded episodes were not treated according to the ColdZyme 398 
IFU). For Tranche 2 (December 2018-April 2019) we provided additional information and regular 399 
reminders to participants to overcome this. These procedures appear to have been effective as poor 400 
compliance with IFU was only evident in 14% of reported episodes, but compliance was still not 401 
entirely optimal (a common problem with free-living human trials). On the one hand, this is a 402 
limitation - possibly reducing the magnitude of effect in the ColdZyme group. However, on the 403 
other hand, separate analysis of the good and bad compliance episodes does provide a useful 404 
comparator condition which may overcome some of the limitations that arise in open label trials 405 
(i.e. potential placebo effects in treatment group), as can be seen in the ColdZyme Good IFU comp 406 
vs ColdZyme Poor IFU comp and ColdZyme Good IFU comp vs Control comparisons.  407 
 408 
The use of self-report methods and illness questionnaires has the limitation of being subjective and 409 
presents the possibility of athletes reporting symptoms/self-reporting illness in the absence of a true 410 
infection. Some studies have reported an increased occurrence of allergy-type symptoms that are 411 
often mistaken by athletes as URTI, although this tends to be more common in spring (Northern 412 
hemisphere), when responses to environmental allergens such as pollen are more common (28). The 413 
current study was conducted in the winter months when URTI-incidence is known to be at a peak. 414 
In addition, the validated Jackson questionnaire and scoring criteria were used, which help to 415 
protect against false positive episode counts (although these can never be completely prevented). It 416 
was not feasible in the present study to confirm infection via laboratory-based diagnostic methods 417 
(e.g. polymerase chain reaction (PCR) detection of URTI-causing pathogens from throat and nasal 418 
swabs and/or bioligical fluids). It would be beneficial for future studies to include these 419 
measurements to 1) confirm the presence of URTI during self-reported episodes, and 2) monitor 420 
viral load during the course of an episode to provide insight into the mechanisms of action (for 421 
example, this would allow greater insight into the pattern of propagation, spread and infection/virus 422 
clearance rate at different sites within the URT).  423 
 424 
Conclusions 425 
It is clear that reporting of upper respiratory illness symptoms in athletes cluster around periods of 426 
intensive training and/or competition (6,7). This can have a direct and significant impact on athletes’ 427 
performance in competition, preparation and training and general wellbeing (6,8,9). In this study we 428 
provide the first evidence from a randomised trial in athletes under free-living conditions on the 429 
effects of a proposed non-nutritional countermeasure (ColdZyme Mouth Spray) to self-reported 430 
URTI in athletes, which may have implications for athletes’ absence from training and athlete 431 
performance. We show that ColdZyme mouth spray used in accordance with manufacturer 432 
instructions can reduce self-reported URTI episode duration (by 3.5 days: ~34% reduction in 433 
episode duration). This was also associated with a reduction in lost training days (~54% reduction, 434 
from 3.5 days lost per episode in Control to 1.6 days lost per episode in ColdZyme). This may 435 
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Table 1: Overview of self-report URTI data 532 
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Figure titles and captions  541 
 542 
Figure 1. Pattern of training load change across study period (% of healthy average).   543 
 544 
Figure 2. Pattern of training load in 2 weeks before URTI onset, during URTI and 3 weeks after 545 
URTI subsided.  546 
Significantly different to ‘healthy’ weeks (** P < 0.01) 547 
548 
Table 1: Overview of self-report URTI data 549 
 Control  ColdZyme 
(overall) 
ColdZyme 
(Poor IFU comp) 
ColdZyme 
(Good IFU comp) 
URTI episodes                          
(per person) 
 
1.1 ± 0.9 1.0 ± 0.8 #n/a #n/a 
URTI episode duration 
(d) 
 
10.4 ± 8.5 *7.7 ± 4.0 9.3 ± 4.5 **†6.9 ± 3.5 
Jackson Symptom Score 
(episode total) 
 
74.9 ± 72.0 **43.6 ± 30.1 52.6 ± 35.7 **40.0 ± 26.5 
Jackson Symptom Score 
(daily episode average) 
6.9 ± 2.8 **5.5 ± 2.4 *5.3 ± 1.7 *5.6 ± 2.7 
NOTE: #n/a = Not relevant or calculated since compliance can only be analysed when an episode exists  550 
ColdZyme Poor IFU comp = Poor compliance with ColdZyme IFU (e.g. less than 4 doses per day); 551 
ColdZyme Good IFU comp = Good compliance with ColdZyme IFU.  552 
Significantly different to Control: * P < 0.05; ** P < 0.01 553 




Table 2: Days that training was affected by URTI episodes/symptoms 558 
 Control ColdZyme 
(overall) 
ColdZyme 
(poor IFU comp) 
ColdZyme 
(good IFU comp) 
Days missed  3.5 ± 5.0 *1.6 ± 2.5 *1.6 ± 2.9 *1.6 ± 2.3 
Days reduced training 3.4 ± 5.1 3.0 ± 3.4 3.1 ± 3.1 2.9 ± 3.7 
Average days missed/reduced per URTI episode 559 
ColdZyme Poor IFU comp = Poor compliance with ColdZyme IFU (e.g. less than 4 doses per day); 560 
ColdZyme Good IFU comp = Good compliance with ColdZyme IFU.  561 






























Figure 2 592 
